LTGO (Latigo Biotherapeutics) Change In Receivables: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTGO Latigo Biotherapeutics Inc LTGO
8 GF Score
Price $18.14
View Full Analysis

What is Latigo Biotherapeutics Change In Receivables?

Latigo Biotherapeutics LTGO -0.60% 8 Change In Receivables is $0.00 Mil as of Dec. 2025. GuruFocus rates LTGO with a GF Score™ of 8/100.

Latigo Biotherapeutics's change in receivables for the quarter that ended in Dec. 2025 was $0.00 Mil. It means Latigo Biotherapeutics's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Latigo Biotherapeutics's change in receivables for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Latigo Biotherapeutics's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Latigo Biotherapeutics's Accounts Receivable for the quarter that ended in Dec. 2025 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Latigo Biotherapeutics's liquidation value for the six months ended in Dec. 2025 was $-237.75 Mil.


Latigo Biotherapeutics  (NAS:LTGO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Latigo Biotherapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

2. In Ben Graham's calculation of liquidation value, Latigo Biotherapeutics's accounts receivable are only considered to be worth 75% of book value:

Latigo Biotherapeutics's liquidation value for the quarter that ended in Dec. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=69.437-307.19+0.75 * 0+0.5 * 0
=-237.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Latigo Biotherapeutics Change In Receivables Related Terms


Latigo Biotherapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Latigo Biotherapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Latigo Biotherapeutics Change In Receivables Chart

Latigo Biotherapeutics Annual Data
Trend Dec24 Dec25
Change In Receivables
0.00 0.00

Latigo Biotherapeutics Semi-Annual Data
Dec24 Dec25
Change In Receivables 0.00 0.00
LTGO
8GF Score
Latigo Biotherapeutics Inc LTGO
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Latigo Biotherapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.00 Mil mean?
Latigo Biotherapeutics (LTGO) has a Change In Receivables of $0.00 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Latigo Biotherapeutics and its competitors.
Is Latigo Biotherapeutics' Change In Receivables too high?
Latigo Biotherapeutics' current Change In Receivables is $0.00 Mil. Overall, Latigo Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Latigo Biotherapeutics' Change In Receivables compare to ?
Latigo Biotherapeutics' Change In Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Latigo Biotherapeutics and its competitors. Latigo Biotherapeutics's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Latigo Biotherapeutics stock overvalued right now?
Latigo Biotherapeutics (LTGO) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. Latigo Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Latigo Biotherapeutics (LTGO), the current Change In Receivables is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Latigo Biotherapeutics Business Description

Comparable Companies
Address 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA, USA, 91320
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
8GF Score

Get the complete analysis for LTGO

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.14
Price